<- All drugs

Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

Bimagrumab plus semaglutide

INVESTIGATIONAL

Activin type II receptor inhibition combined with GLP-1 receptor agonism

graded results

ongoing records

effect domains

Evidence spread

High evidence 0Moderate evidence 1Low evidence 0Very low evidence 1

Bimagrumab plus semaglutide is investigational in the scoped programme below. Study records do not establish approval, safety or personal suitability. Results describe observations and do not provide treatment advice.

Dated status sources

INVESTIGATIONAL Global programme; Obesity and body composition; Co-administered intravenous bimagrumab and subcutaneous semaglutide; as of 2026-07-13. ClinicalTrials.gov

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Bimagrumab plus semaglutide INVESTIGATIONAL

body-composition Mixed

Moderate evidence

BELIEVE phase-2b (Eli Lilly/Versanis) tested bimagrumab alone or added to semaglutide. The combination drove fat-selective weight loss with lean-mass preservation;...

Heymsfield et al., Nat Med 2026; presented ADA 2025 Source

Full findingBELIEVE phase-2b (Eli Lilly/Versanis) tested bimagrumab alone or added to semaglutide. The combination drove fat-selective weight loss with lean-mass preservation; bimagrumab monotherapy GAINED lean while semaglutide alone lost it. Now PEER-REVIEWED (Heymsfield et al., Nat Med 2026).

PopulationBELIEVE phase-2b RCT, N=507, 48-week treatment (results to wk72), randomised double-blind placebo-controlled, 9 arms; bimagrumab IV q12w +/- semaglutide sc weekly; adults overweight/obese with >=1 comorbidity.

Fundingindustry - Eli Lilly (trial sponsor)

Comparatorsplacebo; semaglutide 1.0 mg; semaglutide 2.4 mg; bimagrumab 10 mg/kg; bimagrumab 30 mg/kg

Bimagrumab plus semaglutide INVESTIGATIONAL

body-composition Mixed

Very low evidence

Muscle-preserving combination landscape: bimagrumab (ActRII blockade) is reported to add lean mass while reducing fat, and is being combined with semaglutide to...

Nunn E et al., Mol Metab, 2024 (preclinical); Kaiser M et al., Cardiol Rev, 2025 (review) Source

Full findingMuscle-preserving combination landscape: bimagrumab (ActRII blockade) is reported to add lean mass while reducing fat, and is being combined with semaglutide to counter GLP-1-associated lean-mass loss; preclinical work shows combination preserves muscle while enhancing fat loss vs semaglutide alone.

PopulationPreclinical (diet-induced obese mice) plus clinical-development narrative/review; combination under clinical study

Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)

Comparatorssemaglutide